Pharmaceutical Profits Exposed

Access to clinical trial data is often limited, leaving peer reviewers unable to ensure the accuracy of published results. This system prioritizes profit for pharmaceutical companies and academic institutions over public health, as financial incentives drive complicity among researchers and journals alike. The conversation highlights the urgent need for transparency and accountability in medical research.